The market for home healthcare devices is growing at a steady clip, and Roche is wise to the trend. The Swiss diagnostics giant is launching its PT/INR home self-testing device in Europe, building out its offerings while potentially improving care for patients on anticoagulant therapy.
Roche's Diabetes Care has signed a deal with implantable glucose sensor company Senseonics to sell its Eversense Continuous Glucose Monitoring System in Germany, Italy and the Netherlands. The deal comes just after a CE mark for the system earlier this month.
Genomic test prep company Purigen Biosystems reeled in $18.2 million in a Series A round to support development of its benchtop testing technology.
Some have speculated that Roche would sell off its diabetes testing business amid floundering sales. But at least for now, the company is holding on to the unit.
There's a new leukemia drug in town, and to hear analysts tell it, Venclexta is destined to hit the blockbuster target. Developers AbbVie and Roche say they're ready to roll it out within a week, at a price of $110,000 for the first year of treatment.
India has lifted its alert on the advice of an expert committee, meaning Avastin is once again all clear for off-label eye sales.
AstraZeneca and Roche's Genentech have agreed to bankroll a study of lung cancer patients that will analyze PatientsLikeMe's patient-reported outcomes alongside traditional forms of data. The project is designed to assess the value of giving researchers a broader overview of factors that can affect health outcomes.
Roche is reportedly considering continuing its sequencing dealmaking activity with a bid for Pacific Biosciences.
Shares of Menlo Park's Pacific Biosciences of California are up 25% on a report that Big Pharma (and diagnostics) player Roche is interested in acquiring the provider of gene sequencing technology.
Roche pharma chief Daniel O'Day expects payers to continue piling on the pressure when it comes to drug pricing. He just doesn't expect it to affect his company's cancer stars anytime in the near future.